Last reviewed · How we verify
Pyridium
At a glance
| Generic name | Pyridium |
|---|---|
| Also known as | Group A |
| Sponsor | Texas Tech University Health Sciences Center |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Prophylactic Analgesia for Bladder Botox Injections (PHASE4)
- Effectiveness of Phenazopyridine for Pain Following Urodynamics (PHASE4)
- Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease (PHASE2)
- Identifying Stress Urinary Incontinence in Women With Pelvic Organ Prolapse (NA)
- Investigating Oral Agents for Urine Staining to Facilitate Intraoperative Observation of Ureteral Jets (EARLY_PHASE1)
- Efficacy Study of Methenamine + Methylthioninium Chloride vs Phenazopyridine for the Symptomatic Control of Dysuria (PHASE3)
- Assessing Pyridium for Post-Sling Urinary Retention (PHASE4)
- Evaluation of Ureteral Jets on Cystoscopy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pyridium CI brief — competitive landscape report
- Pyridium updates RSS · CI watch RSS
- Texas Tech University Health Sciences Center portfolio CI